Elan in the hot seat as US judge sides with Biogen Idec in Tysabri fight
This article was originally published in Scrip
Executive Summary
The US federal judge who sided with Biogen Idec in its dispute with Elan over rights to the multiple sclerosis drug Tysabri (natalizumab) has put Elan in a tight spot, and analysts take the view that the company must move fast.